Table 6.
Median [IQR antibody (IgG BAU/ml) to receptor-binding domain (RBD) by brand and age category with Time
| Two doses of BNT162b2 | Two doses of mRNA-1273 | One dose BNT162b2, One dose mRNA-1273 | One dose AstraZeneca Vaxzevria®, one dose BNT162b2 or mRNA-1273 | Other combinations or unknown | pa | |
|---|---|---|---|---|---|---|
| 30–50 Cohort | ||||||
| n | 162 | 61 | 63 | 38 | 13 | |
| 2 Weeks Post 2nd Dose | ||||||
| n (%) with a result | 131 (80.9) | 49 (80.3) | 53 (84.1) | 32 (84.2) | 3 (23.1) | <0.0001 |
| Median [IQR] BAU/mL | 3983 [2331, 7170] | 6030 [4399, 7857] | 6810 [4417, 8829] | 4261 [3122, 6678] | 1278 [864, 3623] | 0.00027 |
| # (%) Positive | 131 (100) | 49 (100) | 53 (100) | 32 (100) | 3 (100) | n/a |
| 24 Weeks Post 2nd Dose | ||||||
| n (%) with a result | 108 (66.7) | 41 (67.2) | 51 (81.0) | 29 (76.3) | 2 (15.4) | 0.00013 |
| Median [IQR] BAU/mL | 227 [133, 499] | 425 [224, 771] | 263 [192, 637] | 204 [127, 354] | 3244 [1740, 4747] | 0.010 |
| # (%) Positive | 107 (99.1) | 41 (100) | 51 (100) | 29 (100) | 2 (100) | 0.89 |
| 48 Weeks Post 2nd Dose | ||||||
| n (%) with a result | 97 (59.9) | 36 (59.0) | 40 (63.5) | 24 (63.2) | 3 (23.1) | 0.10 |
| Median [IQR] BAU/mL | 886 [403, 3382] | 2432 [630, 4557] | 1211 [434, 3886] | 1870 [573, 7751] | 748 [523, 2015] | 0.20 |
| n(%) Positive | 97 (100) | 36 (100) | 40 (100) | 24 (100) | 3 (100) | n/a |
| 70+ Cohort | ||||||
| n | 576 | 71 | 147 | 30 | 21 | |
| 2 Weeks Post 2nd Dose | ||||||
| n (%) with a result | 499 (86.6) | 63 (88.7) | 132 (89.8) | 27 (90.0) | 16 (76.2) | 0.445 |
| Median [IQR] BAU/mL | 1718 [683, 3528] | 5427 [2940, 8829] | 3407 [1586, 6582] | 1775 [904, 5196] | 462 [99, 1123] | <0.0001 |
| # (%) Positive | 488 (97.8) | 62 (98.4) | 131 (99.2) | 27 (100) | 14 (87.5) | 0.032 |
| 24 Weeks Post 2nd Dose | ||||||
| n (%) with a result | 483 (83.9) | 55 (77.5) | 120 (81.6) | 23 (76.7) | 15 (71.4) | 0.34 |
| Median [IQR] BAU/mL | 185 [93, 447] | 451 [237, 1134] | 227 [135, 546] | 135 [96, 283] | 119 [26, 1070] | <0.0001 |
| n (%) Positive | 449 (93.0) | 55 (100) | 115 (95.8) | 21 (91.3) | 10 (66.7) | 0.00014 |
| 48 Weeks Post 2nd Dose | ||||||
| n (%) with a result | 469 (81.4) | 54 (76.1) | 114 (77.6) | 24 (80.0) | 16 (76.2) | 0.71 |
| Median [IQR] BAU/mL | 2444 [689, 5999] | 3618 [1448, 8706] | 3213 [952, 6939] | 3396 [1518, 6536] | 2698 [1225, 5130] | 0.13 |
| n (%) Positive | 460 (98.1) | 53 (98.1) | 114 (100) | 24 (100) | 16 (100) | 0.56 |
IQR, interquartile range; n/a, not applicable; BAU, binding antibody units.
a
p values are from Kruskal-Wallis tests for median BAU/mL values and chi-square tests for n(%) Positive values.